NO20055459L - Prosesser - Google Patents

Prosesser

Info

Publication number: NO20055459L
Authority: NO; Norway
Prior art keywords: genes; gene; responsive; processes; sets
Prior art date: 2003-05-30

Application number

NO20055459A

Other languages

English (en)

Norwegian (no)

Other versions

NO20055459D0 (no

Inventor

Takashi Tsuruo

Yusuke Nakamura

Saburo Sone

Masahiro Fukuoka

Original Assignee

Univ Tokyo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-30

Filing date

2005-11-18

Publication date

2006-02-27

2003-05-30 Priority claimed from GB0312451A external-priority patent/GB0312451D0/en

2003-09-26 Priority claimed from GB0322636A external-priority patent/GB0322636D0/en

2003-11-21 Priority claimed from GB0327132A external-priority patent/GB0327132D0/en

2005-11-18 Application filed by Univ Tokyo filed Critical Univ Tokyo

2005-11-18 Publication of NO20055459D0 publication Critical patent/NO20055459D0/no

2006-02-27 Publication of NO20055459L publication Critical patent/NO20055459L/no

Links

108090000623 proteins and genes Proteins 0.000 abstract 7
102000001301 EGF receptor Human genes 0.000 abstract 1
108060006698 EGF receptor Proteins 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
239000003550 marker Substances 0.000 abstract 1
229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Toxicology (AREA)
Hospice & Palliative Care (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Plant Pathology (AREA)
Pulmonology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO20055459A 2003-05-30 2005-11-18 Prosesser NO20055459L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0312451A GB0312451D0 (en)	2003-05-30	2003-05-30	Process
GB0322636A GB0322636D0 (en)	2003-09-26	2003-09-26	Process
GB0327132A GB0327132D0 (en)	2003-11-21	2003-11-21	Process
PCT/GB2004/002316 WO2005049829A1 (en)	2003-05-30	2004-06-01	Process

Publications (2)

Publication Number	Publication Date
NO20055459D0 NO20055459D0 (no)	2005-11-18
NO20055459L true NO20055459L (no)	2006-02-27

Family

ID=34623472

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20055459A NO20055459L (no)	2003-05-30	2005-11-18	Prosesser

Country Status (12)

Country	Link
US (1)	US20060252056A1 (pt)
EP (2)	EP2348110B1 (pt)
JP (2)	JP4724657B2 (pt)
KR (1)	KR101126560B1 (pt)
AU (1)	AU2004291709C1 (pt)
BR (1)	BRPI0410634A (pt)
CA (1)	CA2527680A1 (pt)
IL (1)	IL172029A (pt)
MX (1)	MXPA05012939A (pt)
NO (1)	NO20055459L (pt)
NZ (1)	NZ543234A (pt)
WO (1)	WO2005049829A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4724657B2 (ja) *	2003-05-30	2011-07-13	アストラゼネカユーケーリミテッド	プロセス
US7700299B2 (en) *	2005-08-12	2010-04-20	Hoffmann-La Roche Inc.	Method for predicting the response to a treatment
ATE520979T1 (de) *	2005-08-24	2011-09-15	Bristol Myers Squibb Co	Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
JP2007135581A (ja) *	2005-10-20	2007-06-07	Japan Science & Technology Agency	自己免疫性血小板減少性紫斑病（ｉｔｐ）患者の血液細胞特異的遺伝子群
FI121236B (fi) *	2006-01-18	2010-08-31	Licentia Oy	Menetelmä asbestialtistukseen liittyvien keuhkosyöpien tunnistamiseksi
CN101415440A (zh)	2006-02-10	2009-04-22	肿瘤疗法科学股份有限公司	治疗肺癌的方法
WO2007099852A1 (ja) *	2006-02-23	2007-09-07	National University Corporation Kanazawa University	固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット
WO2007101122A2 (en) *	2006-02-24	2007-09-07	University Of Chicago	Methods and compositions involving slc17a1
US8288112B2 (en)	2006-04-25	2012-10-16	P&M Venge Ab	Protein, an antibody and measurement of the protein
EP2032719A2 (en)	2006-06-02	2009-03-11	GlaxoSmithKline Biologicals S.A.	Method for identifying whether a patient will be responder or not to immunotherapy
JP5656406B2 (ja) *	2006-11-28	2015-01-21	ユースリーファーマゲゼルシャフトミットベシュレンクテルハフツングＵ３ＰｈａｒｍａＧｍｂＨ	治療効力を予測するためのマーカーとしての活性化ｈｅｒ３
RU2009125575A (ru) *	2006-12-04	2011-01-20	Эбботт Лэборетриз (Us)	Комплексные диагностические анализы для терапии рака
NZ581201A (en)	2007-05-11	2012-05-25	Enzon Pharmaceuticals Inc	Rna antagonist compounds for the modulation of her3
CN101827947B (zh) *	2007-08-14	2013-11-13	霍夫曼-拉罗奇有限公司	Egfr抑制剂治疗的预测性标记物
EP2179058A2 (en) *	2007-08-14	2010-04-28	F. Hoffmann-Roche AG	Predictive marker for egfr inhibitor treatment
AU2008286408A1 (en) *	2007-08-14	2009-02-19	F. Hoffmann-La Roche Ag	Predictive marker for EGFR inhibitor treatment
WO2009021680A1 (en) *	2007-08-14	2009-02-19	F. Hoffmann-La Roche Ag	Predictive marker for egfr inhibitor treatment
BRPI0815372A2 (pt) *	2007-08-14	2019-09-24	Hoffmann La Roche	marcador preditivo para o tratamento com inibidor do egfr
MX2010001582A (es) *	2007-08-14	2010-06-02	Hoffmann La Roche	Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
KR101169244B1 (ko) *	2007-08-14	2012-08-02	에프. 호프만-라 로슈 아게	Ｅｇｆｒ 억제제 치료에 대한 예측 마커
JP2010535519A (ja) *	2007-08-14	2010-11-25	エフ．ホフマン−ラロシュアーゲー	Ｅｇｆｒ阻害剤治療のための予測マーカー
KR101169247B1 (ko) *	2007-08-14	2012-08-03	에프. 호프만-라 로슈 아게	Ｅｇｆｒ 저해제 처리 마커
KR20100037637A (ko) *	2007-08-14	2010-04-09	에프. 호프만-라 로슈 아게	Ｅｇｆｒ 억제제 치료에 대한 예측 마커
WO2010015535A1 (en) *	2008-08-05	2010-02-11	F. Hoffmann-La Roche Ag	Predictive marker for egfr inhibitor treatment
GB0904957D0 (en) *	2009-03-23	2009-05-06	Univ Erasmus Medical Ct	Tumour gene profile
EP2239578A1 (en) *	2009-04-10	2010-10-13	PamGene B.V.	Method for determining the survival prognosis of patients suffering from non-small cell lung cancer (NSCLC)
EP2419522A4 (en) *	2009-04-17	2012-10-31	Glen Weiss	METHOD AND KITS FOR THE FORECASTING OF THERAPY RESULTS OF TYROSINE CHINESE INHIBITORS
GB0917457D0 (en)	2009-10-06	2009-11-18	Glaxosmithkline Biolog Sa	Method
TW201302793A (zh)	2010-09-03	2013-01-16	Glaxo Group Ltd	新穎之抗原結合蛋白
WO2013056153A1 (en) *	2011-10-13	2013-04-18	Kung Charles	Activators of pyruvate kinase m2 and methods of treating disease
TWI582239B (zh) *	2013-03-11	2017-05-11	諾華公司	與ｗｎｔ抑制劑相關之標記
WO2015069187A1 (en)	2013-11-05	2015-05-14	Agency For Science, Technology And Research	Bladder Carcinoma Biomarkers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU661533B2 (en)	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
US5837832A (en)	1993-06-25	1998-11-17	Affymetrix, Inc.	Arrays of nucleic acid probes on biological chips
MX9707453A (es)	1995-03-30	1997-12-31	Pfizer	Derivados de quinazolina.
GB9508538D0 (en)	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
MX9800215A (es)	1995-07-06	1998-03-31	Novartis Ag	Pirrolopirimidas y procesos para su preparacion.
US5760041A (en)	1996-02-05	1998-06-02	American Cyanamid Company	4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
HU228446B1 (en)	1996-04-12	2013-03-28	Warner Lambert Co	Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
US6002008A (en)	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
ATE241986T1 (de)	1997-05-06	2003-06-15	Wyeth Corp	Verwendung von chinazolin verbindungen zur behandlung von polyzystischer nierenkrankheit
TW436485B (en)	1997-08-01	2001-05-28	American Cyanamid Co	Substituted quinazoline derivatives
CN1278176A (zh)	1997-11-06	2000-12-27	美国氰胺公司	喹唑啉衍生物作为用于治疗结肠息肉的酪氨酸激酶抑制剂的应用
RS49779B (sr)	1998-01-12	2008-06-05	Glaxo Group Limited,	Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
TR200003166T2 (tr)	1998-04-29	2001-02-21	Osi Pharmaceuticals, Inc.	N-(3-etinilfenilamino)-6, 7-bis(2-metoksietoksi)-4-kuinozolamin mesilat anhidrat ve monohidrat.
WO2000031048A1 (en)	1998-11-19	2000-06-02	Warner-Lambert Company	N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
JP2000287680A (ja) *	1999-04-09	2000-10-17	Sentan Kagaku Gijutsu Incubation Center:Kk	未成熟肝細胞を成熟肝細胞へ分化させる方法
ATE377597T1 (de)	1999-07-09	2007-11-15	Glaxo Group Ltd	Anilinochinazoline als protein-tyrosin- kinasehemmer
US7194269B2 (en)	2000-10-30	2007-03-20	Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Industry	Method and wireless communication hub for data communications
US7189507B2 (en) *	2001-06-18	2007-03-13	Pdl Biopharma, Inc.	Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
JP2005503145A (ja) *	2001-08-16	2005-02-03	ザユナイテッドステイツオブアメリカリプレゼンティッドバイザシークレタリーデパートメントオブヘルスアンドヒューマンサービシーズ	非小細胞肺癌の分子特性
AU2002353972A1 (en) *	2001-11-02	2003-05-19	Pfizer Products Inc.	Lung cancer therapeutics and diagnostics
US20050208500A1 (en) *	2003-03-04	2005-09-22	Erlander Mark G	Signatures of ER status in breast cancer
JP4724657B2 (ja) *	2003-05-30	2011-07-13	アストラゼネカユーケーリミテッド	プロセス

2004
- 2004-06-01 JP JP2006516368A patent/JP4724657B2/ja not_active Expired - Fee Related
- 2004-06-01 EP EP10012191A patent/EP2348110B1/en not_active Expired - Lifetime
- 2004-06-01 AU AU2004291709A patent/AU2004291709C1/en not_active Ceased
- 2004-06-01 MX MXPA05012939A patent/MXPA05012939A/es active IP Right Grant
- 2004-06-01 EP EP04735607A patent/EP1633870B1/en not_active Expired - Lifetime
- 2004-06-01 NZ NZ543234A patent/NZ543234A/en not_active IP Right Cessation
- 2004-06-01 WO PCT/GB2004/002316 patent/WO2005049829A1/en not_active Ceased
- 2004-06-01 BR BRPI0410634-2A patent/BRPI0410634A/pt not_active IP Right Cessation
- 2004-06-01 CA CA002527680A patent/CA2527680A1/en not_active Abandoned
- 2004-06-01 KR KR1020057020407A patent/KR101126560B1/ko not_active Expired - Fee Related
2005
- 2005-11-17 IL IL172029A patent/IL172029A/en not_active IP Right Cessation
- 2005-11-18 NO NO20055459A patent/NO20055459L/no not_active Application Discontinuation
- 2005-11-30 US US11/290,173 patent/US20060252056A1/en not_active Abandoned
2011
- 2011-02-16 JP JP2011030571A patent/JP5217010B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1633870B1 (en)	2013-03-27
JP2011167188A (ja)	2011-09-01
AU2004291709A1 (en)	2005-06-02
KR20060002012A (ko)	2006-01-06
CA2527680A1 (en)	2005-06-02
KR101126560B1 (ko)	2012-04-05
JP5217010B2 (ja)	2013-06-19
US20060252056A1 (en)	2006-11-09
BRPI0410634A (pt)	2006-06-13
AU2004291709B2 (en)	2009-09-10
JP2006526420A (ja)	2006-11-24
WO2005049829A1 (en)	2005-06-02
JP4724657B2 (ja)	2011-07-13
NO20055459D0 (no)	2005-11-18
EP2348110B1 (en)	2013-03-27
AU2004291709C1 (en)	2010-03-11
MXPA05012939A (es)	2006-05-17
EP2348110A1 (en)	2011-07-27
NZ543234A (en)	2009-04-30
EP1633870A1 (en)	2006-03-15
IL172029A (en)	2011-06-30

Legal Events

Date	Code	Title	Description
2013-02-04	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20055459L (no)	2006-02-27	Prosesser
NO20092023L (no)	2009-06-23	Oligoribonuleotider og anvendelser derav
WO2005029037A3 (en)	2005-12-15	Selective modulation of tlr gene expression
GB2446083A (en)	2008-07-30	Chemically cleavable 3'-0-allyl-dntp-allyl-fluorophore fluorescent nucleotide analogues and related methods
AR059433A1 (es)	2008-04-09	Identificacion y uso de genes blanco para el control de nematodos parasitos de plantas
NO20051469L (no)	2005-05-19	Immunstimulerende nukleinsyrer.
DE60329030D1 (de)	2009-10-08	Melanocortin-rezeptormodulatoren
NO20070263L (no)	2007-03-09	Immunostimulerende oligonukleotidmultimerer
UY28103A1 (es)	2004-06-30	Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
WO2007118198A3 (en)	2008-01-03	2-METHYLENE-1α,25-DIHYDROXY-19,21-DINORVITAMIN D3 ANALOGS AND USES THEREOF
SG143136A1 (en)	2008-06-27	Allophanate-modified stabilizers and the polymer polyols prepared from these stabilizers
WO2008079374A3 (en)	2008-10-30	Methods and compositions for selecting and using single nucleotide polymorphisms
NO20061743L (no)	2006-06-21	Kinazolinderivater
WO2008035207A3 (en)	2008-06-19	2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
MX362199B (es)	2019-01-08	Compuestos y composiciones de poliglicerilo cationicos.
WO2009061941A3 (en)	2009-06-25	Baseless nucleotide analogues and uses thereof
NO20083845L (no)	2008-12-11	2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer
EP1578359A4 (en)	2007-08-01	COMBINATIVE LIBRARIES WITH AUTOINDUCER ANALOGU, AUTOINDUCER AGONISTS AND ANTAGONISTS, AND METHOD OF USE THEREOF
BRPI0514327A (pt)	2008-06-10	compostos triazolopiridina
BRPI0512352A (pt)	2008-03-04	3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
MX2009000654A (es)	2009-07-22	Medios para inhibir la expresion de la cinasa de proteina 3.
SI1644389T1 (sl)	2011-06-30	Pirimidinske spojine s fosfonatnimi skupinami kot antivirusni nukleotidni analogi
EP1734276A3 (de)	2007-02-14	Gasfeder
ATE482948T1 (de)	2010-10-15	Chemische verbindungen
WO2004104199A3 (en)	2005-04-21	Modulation of gene expression using dna-dna hybrids